
WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising a micromolecule PI4KIIIα inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid, the lipid comprises a medium-chain glyceride, and.

2. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor has a structure of formula (I) or a pharmaceutically acceptable salt thereof,



formula (I)

wherein R_1 is each independently selected from H, halogen, nitro, cyano, hydroxyl, amino, carbamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -As(O), -NH-(C_{1-6} alkyl), N,N-(C_{1-6} alkyl)$_2$, -NH-C(O)-R_2, -NH-S(O)$_2$-R_3, -C(O)OR_4 or heterocyclyl, wherein n is an integer of 0-5, R_2 and R_3 are each independently selected from H, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -NH-(C_{1-6} alkyl), N,N-(C_{1-6} alkyl)$_2$, -C(O)OR_4, C_{3-6} cycloalkyl, 6-12 membered aryl or 3-6 membered heterocyclyl, which are optionally substituted by halogen, nitro, cyano, hydroxyl, amino, carbamoyl, aryl, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, 3-6 membered heterocyclyl, C_{3-6} cycloalkyl or Bn-O-, and R_4 is C_{1-6} alkyl.

23. The pharmaceutical composition according to claim 12, wherein R_1 is each independently selected from H, halogen, nitro, cyano, hydroxyl, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl or -As(O), wherein n is an integer of 0-2.

34. The pharmaceutical composition according to claim 12, wherein R_1 is H.

45. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor is at an amount of 0.01-20 mg/g, 0.05-20 mg/g, 0.1-20 mg/g, 0.2-20 mg/g, 0.5-20 mg/g, 0.8-20 mg/g, 1-20 mg/g, 1-18 mg/g, 1-16 mg/g, 1-14 mg/g, 1-12 mg/g, 1-10 mg/g, 2-10 mg/g, 2-8 mg/g, 2-6 mg/g, 3-6 mg/g, 0.2-15 mg/g, 0.2-12 mg/g, 0.2-10 mg/g, 0.2-8 mg/g, 0.2-6 mg/g, 0.2-4 mg/g, 0.2-2 mg/g, 0.2-1 mg/g or 0.2-0.8 mg/g in the

pharmaceutical composition.

56. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier comprises at least about 50% (w/w), at least about 60% (w/w), at least about 70% (w/w), at least about 80% (w/w), at least about 85% (w/w), at least about 90% (w/w), at least about 95% (w/w), at least about 97% (w/w), at least about 98% (w/w), at least about 99% (w/w) or 100% (w/w) of the lipid.

~~7. The pharmaceutical composition according to claim 1, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester is a glyceride, an ethylene glycol ester, a propylene glycol ester or a mixture thereof.~~

~~8. The pharmaceutical composition according to claim 1, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester is a monoester, a diester, a triester or a mixture thereof.~~

~~9. The pharmaceutical composition according to claim 1, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester comprises glycerides of octanoic acid and/or decanoic acid.~~

~~10. The pharmaceutical composition according to claim 1, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester comprises a medium-chain triglyceride.~~

611. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor is phenylarsine oxide, the phenylarsine oxide is at an amount of 0.25-20 mg/g in the pharmaceutical composition, and the pharmaceutically acceptable carrier is consisting of a medium-chain triglyceride, consisting of a medium-chain triglyceride and a long-chain triglyceride, or consisting of a medium-chain triglyceride and ethanol.

712. Use of the pharmaceutical composition according to any one of claims 1-611 in the manufacture of a medicament for treating a PI4KIIIα-related disease in a subject, ~~.~~

~~13. The use according to claim 12,~~ wherein the PI4KIIIα-related disease is Alzheimer's disease.

814. The use according to claim 712, wherein the subject is an animal such as a pig, a dog, a

monkey, a cat, a mouse, or a rat, or a human.

915. The pharmaceutical composition according to any one of claims 1-611 for use in the treatmenting ofa PI4KIIIα-related disease in a subject.